CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Exenatidedrug
Likely dose
Exenatide 5 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01484873
NCT01484873Phase 2Completed
CompareCT.gov

Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity

Vanderbilt University Medical Center·interventional·Posted Dec 2, 2011·Updated Mar 3, 2017

In Brief

A Phase 2 clinical trial evaluating Exenatide for Obesity and 2 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether exenatide can cause weight loss in patients with a history of craniopharyngioma or other brain lesion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight, Craniopharyngioma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2, 2011
Enrollment StartJun 1, 2012
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.6 years ago

Interventions

Exenatidedrug

Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.